Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 26 | 2023 | 1164 | 4.350 |
Why?
|
| alpha-Synuclein | 20 | 2023 | 138 | 3.790 |
Why?
|
| Substantia Nigra | 19 | 2023 | 148 | 2.780 |
Why?
|
| Neurturin | 5 | 2023 | 24 | 1.900 |
Why?
|
| Neurons | 20 | 2023 | 374 | 1.800 |
Why?
|
| Tyrosine 3-Monooxygenase | 18 | 2023 | 83 | 1.500 |
Why?
|
| Prodromal Symptoms | 2 | 2021 | 19 | 1.410 |
Why?
|
| Corpus Striatum | 9 | 2019 | 111 | 1.320 |
Why?
|
| Parkinsonian Disorders | 4 | 2021 | 217 | 1.310 |
Why?
|
| Dopaminergic Neurons | 6 | 2019 | 44 | 1.230 |
Why?
|
| Genetic Therapy | 5 | 2023 | 89 | 1.120 |
Why?
|
| Proto-Oncogene Proteins c-ret | 3 | 2021 | 9 | 1.040 |
Why?
|
| Brain | 11 | 2022 | 1687 | 1.030 |
Why?
|
| Animals | 34 | 2022 | 4577 | 0.970 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 3 | 2021 | 30 | 0.970 |
Why?
|
| Lewy Bodies | 5 | 2022 | 195 | 0.920 |
Why?
|
| Neostriatum | 3 | 2019 | 22 | 0.860 |
Why?
|
| Ribosomal Protein S6 | 1 | 2021 | 3 | 0.790 |
Why?
|
| Dopamine | 9 | 2016 | 156 | 0.700 |
Why?
|
| Down-Regulation | 3 | 2014 | 112 | 0.700 |
Why?
|
| Immunohistochemistry | 15 | 2022 | 391 | 0.650 |
Why?
|
| Aged, 80 and over | 14 | 2022 | 4851 | 0.650 |
Why?
|
| Motor Skills Disorders | 1 | 2018 | 18 | 0.640 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 255 | 0.630 |
Why?
|
| Nerve Tissue Proteins | 5 | 2016 | 173 | 0.620 |
Why?
|
| Alzheimer Disease | 5 | 2023 | 1943 | 0.610 |
Why?
|
| Transcription Factors | 3 | 2015 | 157 | 0.580 |
Why?
|
| Humans | 34 | 2023 | 29361 | 0.550 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 55 | 0.540 |
Why?
|
| Prions | 1 | 2015 | 5 | 0.530 |
Why?
|
| Aged | 17 | 2022 | 9447 | 0.520 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2014 | 2 | 0.500 |
Why?
|
| Male | 28 | 2022 | 15637 | 0.490 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2019 | 453 | 0.480 |
Why?
|
| Female | 26 | 2022 | 16211 | 0.480 |
Why?
|
| Disease Models, Animal | 9 | 2017 | 726 | 0.480 |
Why?
|
| Rats | 10 | 2016 | 858 | 0.460 |
Why?
|
| Macaca fascicularis | 6 | 2021 | 26 | 0.450 |
Why?
|
| Melanins | 4 | 2020 | 11 | 0.440 |
Why?
|
| Dyneins | 1 | 2012 | 2 | 0.440 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2012 | 2 | 0.440 |
Why?
|
| Axonal Transport | 1 | 2012 | 8 | 0.440 |
Why?
|
| Mesencephalon | 4 | 2017 | 44 | 0.430 |
Why?
|
| Aging | 7 | 2010 | 1594 | 0.410 |
Why?
|
| Putamen | 3 | 2020 | 23 | 0.400 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2010 | 2 | 0.390 |
Why?
|
| MADS Domain Proteins | 1 | 2010 | 2 | 0.390 |
Why?
|
| Fetal Tissue Transplantation | 4 | 2016 | 35 | 0.380 |
Why?
|
| Dependovirus | 5 | 2017 | 37 | 0.370 |
Why?
|
| MPTP Poisoning | 4 | 2016 | 16 | 0.370 |
Why?
|
| Cell Count | 6 | 2019 | 99 | 0.370 |
Why?
|
| Fetus | 1 | 2010 | 56 | 0.360 |
Why?
|
| Genetic Vectors | 6 | 2017 | 60 | 0.360 |
Why?
|
| Antiparkinson Agents | 3 | 2016 | 130 | 0.360 |
Why?
|
| Cathepsin D | 1 | 2009 | 2 | 0.350 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2009 | 2 | 0.350 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 15 | 0.350 |
Why?
|
| Middle Aged | 15 | 2020 | 9823 | 0.350 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 3 | 2019 | 13 | 0.310 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2019 | 12 | 0.300 |
Why?
|
| Multiple System Atrophy | 2 | 2018 | 42 | 0.300 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2007 | 44 | 0.290 |
Why?
|
| Amyloid beta-Peptides | 2 | 2023 | 294 | 0.280 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 181 | 0.270 |
Why?
|
| Case-Control Studies | 3 | 2020 | 638 | 0.270 |
Why?
|
| Macaca mulatta | 9 | 2017 | 65 | 0.240 |
Why?
|
| Cerebral Cortex | 5 | 2018 | 195 | 0.230 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 59 | 0.230 |
Why?
|
| Graft Survival | 2 | 2017 | 98 | 0.230 |
Why?
|
| Microglia | 3 | 2019 | 124 | 0.230 |
Why?
|
| tau Proteins | 2 | 2023 | 202 | 0.230 |
Why?
|
| Parkinson Disease, Secondary | 3 | 2007 | 29 | 0.220 |
Why?
|
| Rats, Transgenic | 2 | 2012 | 21 | 0.200 |
Why?
|
| Brain Tissue Transplantation | 4 | 2017 | 25 | 0.200 |
Why?
|
| Densitometry | 1 | 2021 | 10 | 0.200 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 17 | 0.200 |
Why?
|
| Huntington Disease | 2 | 2015 | 60 | 0.190 |
Why?
|
| Lewy Body Disease | 1 | 2022 | 98 | 0.190 |
Why?
|
| Inclusion Bodies | 2 | 2010 | 14 | 0.180 |
Why?
|
| Mutation | 2 | 2014 | 383 | 0.180 |
Why?
|
| Microinjections | 1 | 2019 | 6 | 0.180 |
Why?
|
| Quinolinic Acid | 1 | 2019 | 9 | 0.170 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2019 | 75 | 0.170 |
Why?
|
| Tissue Fixation | 1 | 2018 | 10 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2021 | 483 | 0.160 |
Why?
|
| Protein Folding | 1 | 2018 | 18 | 0.160 |
Why?
|
| Formaldehyde | 1 | 2018 | 14 | 0.160 |
Why?
|
| Autopsy | 3 | 2016 | 335 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2019 | 173 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 161 | 0.160 |
Why?
|
| Mice | 4 | 2015 | 1620 | 0.150 |
Why?
|
| Oligodendroglia | 1 | 2017 | 26 | 0.150 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2006 | 10 | 0.150 |
Why?
|
| Oligopeptides | 2 | 2006 | 30 | 0.140 |
Why?
|
| Cerebellum | 1 | 2016 | 57 | 0.140 |
Why?
|
| Levodopa | 2 | 2016 | 142 | 0.140 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2016 | 54 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2006 | 78 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 80 | 0.130 |
Why?
|
| Axons | 1 | 2015 | 37 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2015 | 124 | 0.120 |
Why?
|
| Nerve Growth Factor | 1 | 2014 | 31 | 0.120 |
Why?
|
| Endopeptidase K | 2 | 2017 | 5 | 0.110 |
Why?
|
| Transgenes | 2 | 2013 | 13 | 0.110 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 116 | 0.100 |
Why?
|
| MEF2 Transcription Factors | 1 | 2010 | 3 | 0.100 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2010 | 9 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2010 | 17 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2010 | 15 | 0.100 |
Why?
|
| Gene Expression | 2 | 2015 | 226 | 0.090 |
Why?
|
| Isotope Labeling | 1 | 2010 | 4 | 0.090 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2010 | 7 | 0.090 |
Why?
|
| Fluorine Radioisotopes | 1 | 2010 | 8 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 250 | 0.090 |
Why?
|
| Adult | 6 | 2013 | 8604 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2015 | 284 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 21 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 32 | 0.090 |
Why?
|
| Reference Values | 2 | 2007 | 227 | 0.080 |
Why?
|
| Cell Transplantation | 1 | 2008 | 29 | 0.080 |
Why?
|
| Neuropeptides | 1 | 2008 | 29 | 0.080 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 49 | 0.080 |
Why?
|
| Adolescent | 2 | 2006 | 2280 | 0.080 |
Why?
|
| Pregnancy | 1 | 2010 | 404 | 0.080 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2008 | 4 | 0.080 |
Why?
|
| Adrenal Medulla | 1 | 2007 | 31 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 195 | 0.070 |
Why?
|
| Deep Brain Stimulation | 1 | 2008 | 74 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2006 | 55 | 0.070 |
Why?
|
| Epilepsy | 1 | 2008 | 104 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2007 | 97 | 0.070 |
Why?
|
| Choroid Plexus | 1 | 2006 | 7 | 0.070 |
Why?
|
| Neurotoxins | 1 | 2006 | 19 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2006 | 42 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 20 | 0.070 |
Why?
|
| Dyskinesias | 1 | 2005 | 35 | 0.070 |
Why?
|
| Cytokines | 1 | 2007 | 348 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2004 | 6 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2004 | 8 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 20 | 0.060 |
Why?
|
| Estradiol | 1 | 2004 | 58 | 0.060 |
Why?
|
| Swine | 2 | 2019 | 80 | 0.060 |
Why?
|
| Cell Line | 2 | 2019 | 299 | 0.060 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 16 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 2 | 2017 | 34 | 0.060 |
Why?
|
| Immunophilins | 1 | 2002 | 2 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 2003 | 15 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2002 | 21 | 0.060 |
Why?
|
| Nerve Regeneration | 1 | 2002 | 14 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 42 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 46 | 0.050 |
Why?
|
| Rats, Inbred F344 | 3 | 2007 | 48 | 0.050 |
Why?
|
| Inflammation | 2 | 2019 | 345 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 108 | 0.050 |
Why?
|
| beta-Globins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2002 | 44 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 432 | 0.050 |
Why?
|
| Phenotype | 1 | 2002 | 357 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2019 | 13 | 0.040 |
Why?
|
| LLC-PK1 Cells | 1 | 2019 | 2 | 0.040 |
Why?
|
| Biomarkers | 1 | 2002 | 692 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 37 | 0.040 |
Why?
|
| Protein Aggregates | 1 | 2018 | 6 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 117 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2017 | 70 | 0.040 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2016 | 2 | 0.040 |
Why?
|
| Calbindins | 1 | 2016 | 3 | 0.040 |
Why?
|
| Caudate Nucleus | 1 | 2016 | 18 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2018 | 676 | 0.040 |
Why?
|
| Astrocytes | 1 | 2017 | 122 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2015 | 5 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 7 | 0.030 |
Why?
|
| Choline O-Acetyltransferase | 2 | 2006 | 14 | 0.030 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2015 | 5 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2015 | 14 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 30 | 0.030 |
Why?
|
| Behavior, Animal | 2 | 2007 | 105 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 74 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 2015 | 55 | 0.030 |
Why?
|
| Age Factors | 2 | 2008 | 845 | 0.030 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2014 | 6 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2014 | 27 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1220 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 88 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 227 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 18 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2014 | 3476 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 150 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2010 | 4 | 0.020 |
Why?
|
| Silver Staining | 1 | 2010 | 5 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 1 | 2010 | 7 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1113 | 0.020 |
Why?
|
| Presynaptic Terminals | 1 | 2010 | 16 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2010 | 45 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2010 | 34 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 138 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 91 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2010 | 144 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 1251 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 9 | 0.020 |
Why?
|
| NADP | 1 | 2008 | 9 | 0.020 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2008 | 55 | 0.020 |
Why?
|
| Cats | 1 | 2008 | 77 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 28 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2008 | 24 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 159 | 0.020 |
Why?
|
| Microelectrodes | 1 | 2008 | 36 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2007 | 13 | 0.020 |
Why?
|
| Syndecan-3 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cell Survival | 1 | 2007 | 169 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 36 | 0.020 |
Why?
|
| Lameness, Animal | 1 | 2006 | 6 | 0.020 |
Why?
|
| Locomotion | 1 | 2006 | 24 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2006 | 199 | 0.020 |
Why?
|
| Sympatholytics | 1 | 2005 | 14 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2005 | 11 | 0.020 |
Why?
|
| Oxidopamine | 1 | 2005 | 24 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 788 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2005 | 321 | 0.020 |
Why?
|
| Child | 1 | 2008 | 1345 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2004 | 28 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 369 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1442 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 55 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 1618 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 126 | 0.010 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2002 | 17 | 0.010 |
Why?
|
| Haplorhini | 1 | 2002 | 12 | 0.010 |
Why?
|
| Lentivirus | 1 | 2002 | 11 | 0.010 |
Why?
|
| Motor Skills | 1 | 2003 | 61 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2002 | 40 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 85 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2003 | 71 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 678 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 495 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 1829 | 0.010 |
Why?
|